Faron Pharmaceuticals Oy
FPHAF · OTC
12/31/2024 | 6/30/2024 | 12/31/2023 | 6/30/2023 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $299 |
| Gross Profit | $0 | $0 | $0 | -$299 |
| % Margin | – | – | – | – |
| R&D Expenses | $5 | $7 | $11 | $9 |
| G&A Expenses | $2 | $5 | $4 | $4 |
| SG&A Expenses | $2 | $5 | $5 | $4 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | -$0 | $0 |
| Operating Expenses | $7 | $11 | $16 | $13 |
| Operating Income | -$7 | -$11 | -$16 | -$13 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$4 | -$3 | -$1 | -$1 |
| Pre-Tax Income | -$12 | -$14 | -$17 | -$14 |
| Tax Expense | -$0 | $0 | $0 | $0 |
| Net Income | -$12 | -$14 | -$17 | -$14 |
| % Margin | – | – | – | – |
| EPS | 0.173 | -0.173 | -0.184 | -0.155 |
| % Growth | 199.8% | 5.9% | -18.7% | – |
| EPS Diluted | 0.173 | -0.173 | -0.184 | -0.155 |
| Weighted Avg Shares Out | 88,518 | 70,452 | 81,159 | 76,139 |
| Weighted Avg Shares Out Dil | 88,518 | 70,452 | 81,159 | 76,139 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $1 | $1 |
| Interest Expense | $4 | $0 | $0 | $1,578 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$7 | -$11 | -$16 | -$13 |
| % Margin | – | – | – | – |